| Market Cap | 760.17M |
| Revenue (ttm) | 8.12M |
| Net Income (ttm) | -212.56M |
| Shares Out | 20.37M |
| EPS (ttm) | -10.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 271,881 |
| Open | 38.36 |
| Previous Close | 38.42 |
| Day's Range | 36.73 - 38.36 |
| 52-Week Range | 26.70 - 91.83 |
| Beta | 2.67 |
| Analysts | Strong Buy |
| Price Target | 116.50 (+212.17%) |
| Earnings Date | May 2, 2025 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance. The company’s platforms include cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and solidus to discover and develop antisense oligonucleotide. It also develops Ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase 3 clinical tr... [Read more]
Financial Performance
In 2024, PRAX's revenue was $8.55 million, an increase of 249.53% compared to the previous year's $2.45 million. Losses were -$182.82 million, 48.3% more than in 2023.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is $116.5, which is an increase of 212.17% from the latest price.
News
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
Chardan Research initiated coverage on Praxis Precision Medicines, Inc. PRAX on Wednesday, citing the potential of its epilepsy franchise.
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: ...
Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies f...
Praxis Precision Medicines to Participate in Upcoming April Conferences
BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies f...
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)
Ulixacaltamide's Phase 3 study was recommended to stop for futility, significantly lowering its chances of success in essential tremor. Investor focus shifts to the epilepsy pipeline, led by vormatrig...
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines to Present at Two February Investor Conferences
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those ...
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced Biogen, Praxis Precision Medicines and Stoke Therapeutics as the founding partners to its Patient Access Program for epilepsy.
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants Dan Ferry - IR, LifeSci Communications Marcio Souza - President & CEO ...
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo...
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period Over 30% of patients achieved seizure freedom status while on relutrigine Meaningful gains observed in alertness, com...
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
Praxis Precision Medicines, Inc. PRAX reported a loss for the second quarter on Tuesday.
Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief ...
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
BOSTON, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for...